Psych Vivas · Psychopharmacology — stimulants and ADHD medications
Stimulants and ADHD medications — cross-table viva
Fellowship viva on ADHD drug mechanisms, doses, comparative evidence, CV safety, diversion, and switching.
On this page & tools
Target exams
FRANZCPMRCPsychABPNMD-DNB
Prompt
Examiner draws columns: Class / Target / Onset / Killer monitoring. Cards: MTA, Cortese NMA, Newcorn, Volkow PET, Cooper, Habel, Hennissen, Wilens SUD meta, Sallee GXR, Michelson ATX, lisdexamfetamine prodrug.
Station structure
Time: 8–10 minutes. Depth: consultant teaching registrar. Expect mechanism → dose → trial name → safety without marketing slogans.[3]
Continue reading
Psychiatry Fellowship Pro
You have read the opening of this viva. The complete unit — every section and its primary-source references — is part of the Psychiatry Fellowship fellowship atlas.
References10Show ledgerHide ledger
- [1]Volkow ND, Wang G, Fowler JS, et al. Therapeutic doses of oral methylphenidate significantly increase extracellular dopamine in the human brain J Neurosci, 2001.PMID 11160455
- [2]The MTA Cooperative Group A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder Arch Gen Psychiatry, 1999.PMID 10591283
- [3]Cortese S, Adamo N, Del Giovane C, et al. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis Lancet Psychiatry, 2018.PMID 30097390
- [4]Newcorn JH, Kratochvil CJ, Allen AJ, et al. Atomoxetine and osmotically released methylphenidate for the treatment of attention deficit hyperactivity disorder: acute comparison and differential response Am J Psychiatry, 2008.PMID 18281409
- [5]Cooper WO, Habel LA, Sox CM, et al. ADHD drugs and serious cardiovascular events in children and young adults N Engl J Med, 2011.PMID 22043968
- [6]Habel LA, Cooper WO, Sox CM, et al. ADHD medications and risk of serious cardiovascular events in young and middle-aged adults JAMA, 2011.PMID 22161946
- [7]Hennissen L, Bakker MJ, Banaschewski T, et al. Cardiovascular Effects of Stimulant and Non-Stimulant Medication for Children and Adolescents with ADHD: A Systematic Review and Meta-Analysis of Trials of Methylphenidate, Amphetamines and Atomoxetine CNS Drugs, 2017.PMID 28236285
- [8]Wilens TE, Faraone SV, Biederman J, et al. Does stimulant therapy of attention-deficit/hyperactivity disorder beget later substance abuse? A meta-analytic review of the literature Pediatrics, 2003.PMID 12509574
- [9]Sallee FR, McGough J, Wigal T, et al. Guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder: a placebo-controlled trial J Am Acad Child Adolesc Psychiatry, 2009.PMID 19106767
- [10]Michelson D, Allen AJ, Busner J, et al. Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study Am J Psychiatry, 2002.PMID 12411225